Our exclusive SmartGuard technology mimics some of the functions of a healthy pancreas to provide you with advanced protection. It takes action for you if your glucose level goes below a preset limit.
Persistent low* episodes reduced from
6 to 1
per year with no additional time spent high.2
reduction (shorter, less intense lows*) means you can recover more quickly and get on with your day.1
* Measured as sensor glucose values.
** Based upon limited sample size and duration of ASPIRE In-Home study
^ Data from only the voluntary CareLink® Personal uploads from the MiniMed 530G system in the U.S. available from October 15, 2013 to November 29, 2015 evaluated. Based on 3,770,311 days of data with 41,287 users (79.7% with SmartGuard on) reporting 2,239,637 SmartGuard events.
1 Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232. Study focused on nocturnal events and conclusions reached subject to limited sample size and duration.
2 Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384-95.
3 Hypoglycemia (Low Blood Glucose). American Diabetes Association website. Accessed December 2015.
4 Not all patients experience these symptoms at 70mg/dL. Symptoms may vary.
Prescription device. Not for everyone.
MiniMed systems featuring SmartGuard technology are intended for the delivery of insulin and continuous glucose monitoring for the management of diabetes mellitus by persons 16 years of age or older who require insulin. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick is required prior to making adjustments to diabetes therapy. WARNING: The Threshold Suspend feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the feature, it is important to read the 530G System User Guide and discuss proper use with your healthcare provider. See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
MiniMed is a registered trademark and SmartGuard is a trademark of Medtronic, MiniMed Inc.
Ascensia, the Ascensia Diabetes Care logo and CONTOUR are trademarks and/or registered trademarks of Ascensia Diabetes Care.